178 related articles for article (PubMed ID: 36335201)
1. Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.
Chen X; Yang P; Qiao Y; Ye F; Wang Z; Xu M; Han X; Song L; Wu Y; Ou WB
Sci Rep; 2022 Nov; 12(1):18830. PubMed ID: 36335201
[TBL] [Abstract][Full Text] [Related]
2. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.
Dogan S; Frosina D; Geronimo JA; Hernandez E; Mohanty A; Bale T; Hechtman JF; Arcila ME; Hameed MR; Jungbluth AA
Hum Pathol; 2020 Dec; 106():45-53. PubMed ID: 33017591
[TBL] [Abstract][Full Text] [Related]
3. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
[TBL] [Abstract][Full Text] [Related]
4. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Kato Y; Kaneko MK
Biochem Biophys Res Commun; 2013 Apr; 433(4):374-8. PubMed ID: 23524262
[TBL] [Abstract][Full Text] [Related]
5. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
6. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.
Dogan S; Frosina D; Fayad M; de Oliveira TB; Alemar B; Rosenblum M; Tang LH; Hameed M; Xu B; Ghossein RA; Chute DJ; Weigelt B; Jungbluth AA
Mod Pathol; 2019 Feb; 32(2):205-215. PubMed ID: 30206411
[TBL] [Abstract][Full Text] [Related]
7. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
8. Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
Raynaud S; Carbuccia N; Colin C; Adélaïde J; Mozziconacci MJ; Metellus P; Chinot O; Birnbaum D; Chaffanet M; Figarella-Branger D
Oncol Lett; 2010 Sep; 1(5):883-884. PubMed ID: 22966399
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
11. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Kaneko MK; Morita S; Tsujimoto Y; Yanagiya R; Nasu K; Sasaki H; Hozumi Y; Goto K; Natsume A; Watanabe M; Kumabe T; Takano S; Kato Y
Biochem Biophys Res Commun; 2013 Mar; 432(1):40-5. PubMed ID: 23376717
[TBL] [Abstract][Full Text] [Related]
12. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
[TBL] [Abstract][Full Text] [Related]
14. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
15. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
Luo LQ; Peng ZY; Liu X; Yu WZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
[TBL] [Abstract][Full Text] [Related]
16. Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation.
Kawakami S; Ochiai K; Kato Y; Michishita M; Hirama H; Obara R; Azakami D; Watanabe M; Omi T
J Vet Med Sci; 2018 Jan; 80(1):85-91. PubMed ID: 29162772
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
19. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Lee WY; Chen KC; Chen HY; Chen CY
Biomed Res Int; 2014; 2014():364625. PubMed ID: 24995286
[TBL] [Abstract][Full Text] [Related]
20. IDH2 mutation in gliomas including novel mutation.
Koh J; Cho H; Kim H; Kim SI; Yun S; Park CK; Lee SH; Choi SH; Park SH
Neuropathology; 2015 Jun; 35(3):236-44. PubMed ID: 25495392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
